# NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

> **NCT06963021** · PHASE3 · RECRUITING · sponsor: **Neurocrine Biosciences** · enrollment: 200 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** NBI-1065845
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06963021
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06963021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06963021, "NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06963021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*